NGR-bearing human adenovirus type 5 infects cells in flotillin- or caveolin-mediated manner depending on the NGR insertion site. Božinović K, Nestić D, Grellier E, Raddi N, Cornilleau G, Ambriović-Ristov A, Benihoud K, Majhen D.Biomater Adv. 2023 Nov 3;155:213681. doi: 10.1016/j.bioadv.2023.213681. Online ahead of print. PMID: 37944448

Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines. Filipić B, Pantelić I, Nikolić I, Majhen D, Stojić-Vukanić Z, Savić S, Krajišnik D.Vaccines (Basel). 2023 Jun 29;11(7):1172. doi: 10.3390/vaccines11071172.

Human Adenovirus Type 26 Infection Mediated by αvβ3 Integrin Is Caveolin-1-Dependent. Nestić D, Custers J, Švec D, Majhen D.Microbiol Spectr. 2022 Aug 4:e0109722. doi: 10.1128/spectrum.01097-22. Online ahead of print.

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10. Bates EA, Davies JA, Váňová J, Nestić D, Meniel VS, Koushyar S, Cunliffe TG, Mundy RM, Moses E, Uusi-Kerttula HK, Baker AT, Cole DK, Majhen D, Rizkallah PJ, Phesse T, Chester JD, Parker AL.Mol Ther Oncolytics. 2022 Mar 16;25:43-56. doi: 10.1016/j.omto.2022.03.007. eCollection 2022 Jun 16.

Human Adenovirus Type 26 Induced IL-6 Gene Expression in an αvβ3 Integrin- and NF-κB-Dependent Manner. Nestić D, Božinović K, Drašković I, Kovačević A, van den Bosch J, Knežević J, Custers J, Ambriović-Ristov A, Majhen D.Viruses. 2022 Mar 24;14(4):672. doi: 10.3390/v14040672.

Human adenovirus type 26 basic biology and its usage as vaccine vector. Majhen D.Rev Med Virol. 2022 Mar 12:e2338. doi: 10.1002/rmv.2338.

The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal. Nestić D, Božinović K, Pehar I, Wallace R, Parker AL, Majhen D.Pharmaceutics. 2021 Sep 29;13(10):1585. doi: 10.3390/pharmaceutics13101585.

Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Schijns V, Majhen D, van der Ley P, Thakur A, Summerfield A, Berisio R, Nativi C, Fernández-Tejada A, Alvarez-Dominguez C, Gizurarson S, Zamyatina A, Molinaro A, Rosano C, Jakopin Ž, Gursel I, McClean S.Pharmaceutics. 2021 Apr 6;13(4):501. doi: 10.3390/pharmaceutics13040501.

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Hulin-Curtis SL, Davies JA, Nestić D, Bates EA, Baker AT, Cunliffe TG, Majhen D, Chester JD, Parker AL.Cancer Gene Ther. 2020 Nov;27(10-11):785-798. doi: 10.1038/s41417-019-0156-0.